SCHEMBL7101305

SCHEMBL7101305

Cc1c(C=O)cc(Br)cc1[N+](=O)[O-]

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 6/20 0.65
CYP1A2 P05177 1/20 0.49
MAPT P10636 3/20 0.45
ALDH1A1 P00352 2/20 0.45
CYP3A4 P08684 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALOX15 P16050 1/20 0.45
PRKDC P78527 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
HTT P42858 1/20 0.40
TDP1 Q9NUW8 2/20 0.38
CCR6 P51684 1/20 0.38
S100A4 P26447 1/20 0.37
TRPV1 Q8NER1 1/20 0.37
ALDH3A1 P30838 1/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5201165 0.82 CYP1A2 (0.61) ERN1CYP1A2ALDH1A1CYP3A4KDM4E
SCHEMBL7103655 0.81 GPR35 (0.52) ERN1CYP1A2MAPTALDH1A1CYP3A4
SCHEMBL15776593 0.79 CYP3A4 (0.45) ERN1CYP1A2MAPTALDH1A1CYP3A4
SCHEMBL15776986 0.79 MAPT (0.47) ERN1CYP1A2MAPTALDH1A1CYP3A4
SCHEMBL928630 0.79 ERN1 (1.00) ERN1MAPTALDH1A1KDM4EMEN1
SCHEMBL5213406 0.78 ERN1 (0.59) ERN1CYP1A2MAPTALDH1A1CYP3A4
SCHEMBL629542 0.77 CYP1A2 (0.55) ERN1CYP1A2ALDH1A1CYP3A4HSD17B10
SCHEMBL13280627 0.77 CYP1A2 (0.66) ERN1CYP1A2MAPTALDH1A1CYP3A4
SCHEMBL20576955 0.76 CYP1A2 (0.53) ERN1CYP1A2ALDH1A1CYP3A4TDP1
SCHEMBL30915596 0.76 CYP1A2 (0.53) ERN1CYP1A2ALDH1A1CYP3A4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117580836-A Pyrimidine ring structure derivative and application thereof 四川汇宇制药股份有限公司 2024-02-20 CN disclosed
WO-2022268209-A1 DERIVATIVE HAVING PYRIMIDINE-FUSED CYCLIC STRUCTURE, AND USE THEREOF 四川汇宇制药股份有限公司 2022-12-29 WO disclosed
EP-2681216-B1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS EPIZYME INC (US) 2017-09-27 EP disclosed
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ABBOTT LABORATORIES 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ADRA1D, ADRB1, ADRA1A ERN1 1414/4885CYP1A2 587/4885MAPT 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.